Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway

Wei, Zhun; Zheng, Di; Pi, Wenfeng; Qiu, Yonglong; Xia, Kezhou; Guo, Weichun

doi:10.1016/j.jbo.2023.100468

Cited by 5 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isoquercitrin remarkably suppressed the proliferative rate, triggered EMT‐associated migratory and invasive activity, and promoted apoptosis in OS cells in vitro. Moreover, β‐catenin together with its downstream genes (survivin, cyclin D1, and c‐Myc) were remarkably downregulated 272 . Tie et al 273 .…”

Section: Mechanism Of Targeting Signaling Pathwaysmentioning

confidence: 99%

“…Moreover, β-catenin together with its downstream genes (survivin, cyclin D1, and c-Myc) were remarkably downregulated. 272 Tie et al 273 showed that icariin induced apoptosis and inhibited the growth of OS cells by downregulating the Wnt/β-catenin pathway and attenuating the expression of TOPFlash fluorescence. Conversely, TOPFlash fluorescence expression and adenovirus overexpression of β-catenin reversed the inhibitory impact of icariin.…”

Section: 22mentioning

confidence: 99%

See 1 more Smart Citation

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Shen

Lan

et al. 2023

MedComm

View full text Add to dashboard Cite

Osteosarcoma (OS) is a highly prevalent bone malignancy among adolescents, accounting for 40% of all primary malignant bone tumors. Neoadjuvant chemotherapy combined with limb‐preserving surgery has effectively reduced patient disability and mortality, but pulmonary metastases and OS cells' resistance to chemotherapeutic agents are pressing challenges in the clinical management of OS. There has been an urgent need to identify new biomarkers for OS to develop specific targeted therapies. Recently, the continued advancements in genomic analysis have contributed to the identification of clinically significant molecular biomarkers for diagnosing OS, acting as therapeutic targets, and predicting prognosis. Additionally, the contemporary molecular classifications have revealed that the signaling pathways, including Wnt/β‐catenin, PI3K/AKT/mTOR, JAK/STAT3, Hippo, Notch, PD‐1/PD‐L1, MAPK, and NF‐κB, have an integral role in OS onset, progression, metastasis, and treatment response. These molecular classifications and biological markers have created new avenues for more accurate OS diagnosis and relevant treatment. We herein present a review of the recent findings for the modulatory role of signaling pathways as possible biological markers and treatment targets for OS. This review also discusses current OS therapeutic approaches, including signaling pathway‐based therapies developed over the past decade. Additionally, the review covers the signaling targets involved in the curative effects of traditional Chinese medicines in the context of expression regulation of relevant genes and proteins through the signaling pathways to inhibit OS cell growth. These findings are expected to provide directions for integrating genomic, molecular, and clinical profiles to enhance OS diagnosis and treatment.

show abstract

Section: Mechanism Of Targeting Signaling Pathwaysmentioning

confidence: 99%

Section: 22mentioning

confidence: 99%

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Shen

Lan

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…U2OS, HOS [84] Chelerythrine Toddalia asiatica L. U2OS, MG-63 [85] Andrographolide Andrographis paniculata U2OS [86] Rhaponticin Rheum palmatum L. MC3T3-E1, MG-63 [87] Wnt/β-catenin pathway Piperine Piper nigrum L. U2OS, 143B [88] Icariin Epimedium brevicornu Maxim. 143B [89] Isoquercitrin Bidens pilosa L. 143B, U2OS [90] Polydatin Reynoutria japonica Houtt. MG-63, Saos-2 [91] Curcumin Curcuma longa L. U2OS [92] Baicalein Rhizoma coptidis 143B, MG-63, U2OS [93] Allicin Allium sativum Saos-2, U2OS [94] Cantharidin Mylabris phalerata Pallas U2OS, 143B, Saos-2, MG-63, MNNG [95] Cinnamaldehyde Cinnamomum cassia Presl 143B, U2OS, Saos-2, MG-63, HEB, HS5, LO2 [96] Lycorine Lyco salvia miltiorrhiza 143B, MG-63, Saos-2, U2OS [97] JAK/STAT3 pathway Notoginsenoside R1 Panax notoginseng U2OS, MG-63 [98] Polydatin Reynoutria japonica Houtt.…”

Section: Signaling Pathwaymentioning

confidence: 99%

“…Ren et al [89] found that icariin could inhibit the activity of Wnt/β-catenin signaling pathway, down-regulate the expression levels of VEGF, MMP-9, p-GSK3β, p-β-catenin, C-myc and CyclinD1 protein, and promote the expression levels of Cleaved-caspase-3 protein, so as to inhibit the proliferation of OS cells and promote the apoptosis of OS cells. Wei et al [90] experimentally found that isoquercitrin inhibited OS cell proliferation and metastasis, promoted OS cell apoptosis, and delayed the development of OS to some extent by inhibiting the Wnt/β-catenin signaling pathway and down-regulating the expression of β-catenin and its downstream targets C-myc, CyclinD1 and Survivin protein. Luce et al [91] experimentally found that polydatin induced differentiation of human OS cells alone or in the presence of ionizing therapy by secreting sphingolipids and ceramides, suggesting that polydatin could serve as a potential candidate to assist in enhancing radiation-induced anticancer effects.…”

Section: Targeted Therapy Of Os By Signaling Cascade Associated With ...mentioning

confidence: 99%

Effect of traditional Chinese medicine in osteosarcoma: Cross-interference of signaling pathways and potential therapeutic targets

Liu,

Jiang,

et al. 2024

Medicine

View full text Add to dashboard Cite

Osteosarcoma (OS) has a high recurrence rate, disability rate, mortality and metastasis, it brings great economic burden and psychological pressure to patients, and then seriously affects the quality of life of patients. At present, the treatment methods of OS mainly include radiotherapy, chemotherapy, surgical therapy and neoadjuvant chemotherapy combined with limb salvage surgery. These treatment methods can relieve the clinical symptoms of patients to a certain extent, and also effectively reduce the disability rate, mortality and recurrence rate of OS patients. However, because metastasis of tumor cells leads to new complications, and OS cells become resistant with prolonged drug intervention, which reduces the sensitivity of OS cells to drugs, these treatments still have some limitations. More and more studies have shown that traditional Chinese medicine (TCM) has the characteristics of “multiple targets and multiple pathways,” and can play an important role in the development of OS through several key signaling pathways, including PI3K/AKT, Wnt/β-catenin, tyrosine kinase/transcription factor 3 (JAK/STAT3), Notch, transforming growth factor-β (TGF-β)/Smad, nuclear transcription factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), nuclear factor E2-related factor 2 (Nrf2), Hippo/YAP, OPG/RANK/RANKL, Hedgehog and so on. In this paper, the signaling pathways of cross-interference between active ingredients of TCM and OS were reviewed, and the development status of novel OS treatment was analyzed. The active ingredients in TCM can provide therapeutic benefits to patients by targeting the activity of signaling pathways. In addition, potential strategies for targeted therapy of OS by using ferroptosis were discussed. We hope to provide a unique insight for the in-depth research and clinical application of TCM in the fields of OS growth, metastasis and chemotherapy resistance by understanding the signaling crosstalk between active ingredients in TCM and OS.

show abstract

“…TME is composed of EV secretion cells, MSC, and tumour cells. The EV cells are secreted by MSC and immune cells to alter macrophage phenotype-2 (M2) [78] and regulate tumour progression via the Wnt signalling pathway [79]. Furthermore, the EV cells are the paracrine factors secreted by human bone marrow MSC (BMSC), such as osteoclasts, osteoblasts, and endothelial cells, to regulate tumour cells via communication with the Hedgehog signalling pathway [80].…”

Section: Tumorigenesismentioning

confidence: 99%

Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance

Zaidi¹,

Haque²,

Miskon³

2023

Preprint

View full text Add to dashboard Cite

There has been no significant efficacy in treatment for osteosarcoma (OS) metastasis after nearly four decades of trials. This motivates us to elucidate OS therapies according to their four bidirectional mutation stages. To refresh the OS therapy status quo, the historical developments and clinical advancements are briefly described. However, the main issue of metastasis remains unresolved, accounting for 90% of pulmonary metastasis deaths. Thus, this metastasis problem is related to immune evasion and chemoresistance that are being induced after long-term treatment by the use of immunotherapy for tumorigenesis. Therefore, it is rationale to discuss the relationship cycles of mutation stages including tumorigenesis, metastasis, immune evasion, and chemoresistance. Even though many combinational and targeted therapies have been developed to intensify these mutation treatments, successful clinical translations with higher cure rates are still rare. Through this review, an in-depth understanding of the bidirectional relationship between the four OS mutation stages and their respective therapies is provided. Herein, we summarise the medicines used to treat tumorigenesis, including COLGALT2 inhibitors, Tra2B, and AGAP1, miR-148a and miR-21-5p EVs, and the lncRNA LIFR-AS1. Following the medicines used to treat metastasis are AXL, miR-135a-5p, mRNA BCL6, TGFβ1, Tim-3, SOCS5, CASC15, KLF3-AS1, PDCD4, ATG5, and Rab22a-NeoF1. Then the medicines used to treat immune evasion are N-cadherin, anti-IL-9, USP12 inhibitor, IgG-4+ B-cells, LAP inhibitor, anti-Wnt2 mAb, anti-αvβ8 integrin, HK2-mediated IκBα, IDO inhibitor with NO, and TGF-βRII with anti-IgG1. Finally, the medicines used to treat chemoresistance are DHFR, FPGS, HSP-90AA1, XCT-790, ATKI, and IGF1. As a result, this contribution is expected to serve as a reference and guide for scientists and clinicians.

show abstract

Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway

Cited by 5 publications

References 35 publications

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Effect of traditional Chinese medicine in osteosarcoma: Cross-interference of signaling pathways and potential therapeutic targets

Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance

Contact Info

Product

Resources

About